DK1339862T3 - Fotokemisk internalisering til virus-medieret molekyle-delivery ind i cytosolen - Google Patents

Fotokemisk internalisering til virus-medieret molekyle-delivery ind i cytosolen Download PDF

Info

Publication number
DK1339862T3
DK1339862T3 DK01998645.4T DK01998645T DK1339862T3 DK 1339862 T3 DK1339862 T3 DK 1339862T3 DK 01998645 T DK01998645 T DK 01998645T DK 1339862 T3 DK1339862 T3 DK 1339862T3
Authority
DK
Denmark
Prior art keywords
cells
molecule
viral
carrier
photosensitizer
Prior art date
Application number
DK01998645.4T
Other languages
English (en)
Inventor
Anders Hogset
Kristian Berg
Gunnhild Mari Maelandsmo
Birgit Ovsteboe Engesaeter
Lina Prasmickaite
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0029142A external-priority patent/GB0029142D0/en
Priority claimed from GB0029405A external-priority patent/GB0029405D0/en
Priority claimed from GB0114696A external-priority patent/GB0114696D0/en
Application filed by Pci Biotech As filed Critical Pci Biotech As
Application granted granted Critical
Publication of DK1339862T3 publication Critical patent/DK1339862T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
DK01998645.4T 2000-11-29 2001-11-29 Fotokemisk internalisering til virus-medieret molekyle-delivery ind i cytosolen DK1339862T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0029142A GB0029142D0 (en) 2000-11-29 2000-11-29 Method
GB0029405A GB0029405D0 (en) 2000-12-01 2000-12-01 Method
GB0114696A GB0114696D0 (en) 2001-06-15 2001-06-15 Method
PCT/GB2001/005281 WO2002044395A1 (en) 2000-11-29 2001-11-29 Photochemical internalization for virus-mediated molecule delivery into the cyosol

Publications (1)

Publication Number Publication Date
DK1339862T3 true DK1339862T3 (da) 2014-02-17

Family

ID=27255992

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01998645.4T DK1339862T3 (da) 2000-11-29 2001-11-29 Fotokemisk internalisering til virus-medieret molekyle-delivery ind i cytosolen

Country Status (16)

Country Link
US (1) US7521239B2 (da)
EP (1) EP1339862B1 (da)
JP (1) JP4638654B2 (da)
KR (2) KR101180548B1 (da)
CN (1) CN100490902C (da)
AU (2) AU2002222104B2 (da)
BR (1) BRPI0115794B1 (da)
CA (1) CA2430334C (da)
CZ (1) CZ303792B6 (da)
DK (1) DK1339862T3 (da)
ES (1) ES2445579T3 (da)
HK (1) HK1055137A1 (da)
HU (1) HU230334B1 (da)
PL (1) PL213376B1 (da)
PT (1) PT1339862E (da)
WO (1) WO2002044395A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323699D0 (en) * 2003-10-09 2003-11-12 Univ London Use of photosensitisation
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
GB0811955D0 (en) * 2008-06-30 2008-07-30 Pci Biotech As Method
US8808733B2 (en) 2009-03-31 2014-08-19 The Board Of Trustees Of The University Of Arkansas Method of controlled drug release from a liposome carrier
GB0914286D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Method
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
LU91641B1 (en) * 2010-01-21 2011-07-22 Ct De Rech Public Gabriel Lippmann Cancerous or pre-cancerous tissue visualization method and device
JP5885743B2 (ja) * 2011-07-01 2016-03-15 Ｓｂｉファーマ株式会社 光増感剤又は５−アミノレブリン酸類を用いる光線力学的治療
EP2776013B8 (en) 2011-11-08 2023-08-30 The Board of Trustees of the University of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
WO2015028575A1 (en) * 2013-08-28 2015-03-05 Pci Biotech As Immunisation method by photochemical internalisation
AU2014314149B2 (en) * 2013-08-28 2019-12-19 Pci Biotech As Compound and method for vaccination and immunisation
EP3209303A4 (en) * 2014-10-24 2017-08-30 Avectas Limited Delivery across cell plasma membranes
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
KR101936559B1 (ko) * 2016-07-13 2019-01-09 국립암센터 분해가능 연결자를 포함하는 광증감제-펩타이드 결합체 및 그를 포함하는 광역학 진단 또는 치료용 조성물
GB201718631D0 (en) * 2017-11-10 2017-12-27 Pci Biotech As Method
GB201801169D0 (en) * 2018-01-24 2018-03-07 Pci Biotech As Method
WO2020017962A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
CA3133410A1 (en) 2019-04-25 2020-10-29 Dcprime B.V. Methods of tumor vaccination
CA3172447A1 (en) 2020-03-27 2021-09-30 Erik Hans MANTING In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
JP2023519346A (ja) 2020-03-27 2023-05-10 メンドゥス・ベスローテン・フェンノートシャップ 養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用
US20220168407A1 (en) 2020-11-05 2022-06-02 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
WO2024068795A1 (en) * 2022-09-27 2024-04-04 Pci Biotech As Method for releasing viral vectors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
CA1291710C (en) 1985-04-30 1991-11-05 Jerry C. Bommer Tetrapyrrole therapeutic agents
NO891491D0 (no) 1987-08-12 1989-04-11 Peter Nemeth Prosedyre for befrielse av celleblandinger og vev for uoenskede populasjoner.
GB8721108D0 (en) 1987-09-08 1987-10-14 Salford University Of Liposomes
NO176947C (no) 1988-07-06 1995-06-28 Long Island Jewish Medical Ct Fremgangsmåte for fremstilling av et topisk preparat for fotodynamisk terapi
US5059619A (en) 1989-06-14 1991-10-22 Quadra Logic Technologies, Inc. Stable freeze-dried polyhematoporphyrin ether/ester
NO179410C (no) 1989-07-17 1996-10-02 Univ British Columbia Analogifremgangsmåte for fremstilling av terapeutisk aktive monobenzofyriner og anvendelse av disse
US5179120A (en) 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
PL165249B1 (pl) 1991-10-29 1994-11-30 Wojskowa Akad Tech Sposób otrzymywania soli kompleksowych hematoporfiryny i jej pochodnych PL PL PL PL PL PL PL
US5368841A (en) * 1993-02-11 1994-11-29 The General Hospital Corporation Photodynamic therapy for the destruction of the synovium in the treatment of rheumatoid arthritis and the inflammatory arthritides
GB9318841D0 (en) 1993-09-10 1993-10-27 Res Foundation Of The Norwegia Composition
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
DE122006000051I2 (de) * 1995-03-10 2010-07-08 Photocure Asa Hoffsveien 48 Ester der 5-Aminolevulinsäure als Mittel zur Photosensibilisierung in der Chemotherapie
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
GB9700396D0 (en) 1997-01-10 1997-02-26 Photocure As Photochemotherapeutic compositions
EP1177795B1 (en) * 1997-05-07 2013-09-11 QLT Inc. Use of ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents
AU767195B2 (en) 1999-03-10 2003-11-06 Phogen Limited Delivery of substances to cells
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
GB0018527D0 (en) 2000-07-27 2000-09-13 Photocure Asa Composition

Also Published As

Publication number Publication date
HUP0402626A3 (en) 2012-09-28
AU2210402A (en) 2002-06-11
HUP0402626A2 (hu) 2005-03-29
BRPI0115794B1 (pt) 2015-09-15
EP1339862A1 (en) 2003-09-03
ES2445579T3 (es) 2014-03-04
CZ20031792A3 (cs) 2003-10-15
CZ303792B6 (cs) 2013-05-09
KR101180548B1 (ko) 2012-09-06
CN1484706A (zh) 2004-03-24
HU230334B1 (hu) 2016-02-29
PL213376B1 (pl) 2013-02-28
JP4638654B2 (ja) 2011-02-23
AU2002222104B2 (en) 2007-06-28
US7521239B2 (en) 2009-04-21
WO2002044395A1 (en) 2002-06-06
HK1055137A1 (en) 2003-12-24
JP2004520020A (ja) 2004-07-08
US20040096425A1 (en) 2004-05-20
CA2430334A1 (en) 2002-06-06
CN100490902C (zh) 2009-05-27
KR20090016736A (ko) 2009-02-17
KR20030074633A (ko) 2003-09-19
PL362795A1 (en) 2004-11-02
PT1339862E (pt) 2014-02-17
CA2430334C (en) 2018-08-21
EP1339862B1 (en) 2014-01-08
BR0115794A (pt) 2004-02-25

Similar Documents

Publication Publication Date Title
DK1339862T3 (da) Fotokemisk internalisering til virus-medieret molekyle-delivery ind i cytosolen
US8008077B2 (en) Photochemical internalization for delivery of molecules into the cytosol
AU2002222104A1 (en) Photochemical internalization for virus-mediated molecule delivery into the cyosol
AU2002220853A1 (en) Photochemical internalization for delivery of molecules into the cytosol
JP2004520020A5 (da)
Hogset et al. Light directed gene transfer by photochemical internalisation
JP4423508B2 (ja) 癌遺伝子治療薬
RU2333246C2 (ru) Фотохимическая интернализация для доставки молекул в цитозоль